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Background: Insulin treatment can lead to good glycemic control and result in improvement of lipid parameters in type
2 diabetic patients. This study was designed to evaluate the effect of insulin analog initiation therapy on low-density
lipoprotein (LDL)/ high-density lipoprotein (HDL) sub-fractions and HDL associated enzymes in type 2 diabetic patients
during early phase.
Methods: Twenty four type 2 diabetic patients with glycosylated hemoglobin (HbA1c) levels above 10% despite
ongoing combination therapy with sulphonylurea and metformin were selected. Former treatment regimen was
continued for the first day followed by substitution of sulphonylurea therapy with different insulin analogs (0.4 U/kg/day)
plus metformin. Glycemic profiles were determined over 72 hours by continuous glucose monitoring system (CGMS)
and blood samples were obtained from all patients at 24 and 72 hours. Plasma levels of cholesteryl ester transfer protein
(CETP), lecithin-cholesterol acyltransferase (LCAT), apolipoprotein B (apoB) and apolipoprotein A-1 (apoA-I) were
determined by enzyme-linked immunosorbent assay (ELISA). Measurement of CETP and LCAT activity was performed via
fluorometric analysis. Paraoxonase (PON1) enzyme activity was assessed from the rate of enzymatic hydrolysis of phenyl
acetate to phenol formation. LDL and HDL subfraction analysis was done by continuous disc polyacrylamide gel
electrophoresis.
Results: Mean blood glucose, total cholesterol (TC), triglyceride (TG) and very low-density lipoprotein cholesterol
(VLDL-C) levels were significantly decreased while HDL-C levels were significantly increased after insulin treatment.
Although LDL-C levels were not significantly different before and after insulin initiation therapy a significant increase in
LDL-1 subgroup and a significant reduction in atherogenic LDL-3 and LDL-4 subgroups were observed. Insulin analog
initiation therapy caused a significant increase in HDL-large, HDL- intermediate and a significant reduction in HDL-small
subfractions. CETP protein level and activity was significantly increased while apoB levels were significantly decreased
following insulin analog initiation therapy. No significant difference was found in LCAT mass, LCAT activity, apoA-I and
PON-1 arylesterase levels following insulin initiation therapy.
Conclusion: These findings indicate that insulin analog initiation therapy activates lipid metabolism via up-regulating
CETP and shows anti-atherogenic effects by increasing HDL-large and decreasing LDL-3 and LDL-4 subfractions in a
short time period.
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Table 1 Patient characteristics and laboratory values
Variable Mean ± SD n Reference range
Age (years) 52.58 ± 11.43 24
BMI (kg/m2) 25.89 ± 2.26 24
BUN (mg/dl) 12.96 ± 3.50 24 6.00 - 20.00
Serum Creatinine (mg/dl) 0.79 ± 0.17 24 0.50 - 1.20
Microalbumin (mg/24 h) 24.75 ± 18.15 24 0.00 – 30.00
ALT (U/L) 21.71 ± 10.74 24 0.00 – 41.00
AST (U/L) 23.88 ± 10.88 24 0.00- 38.00
TSH (μU/L) 1.05 ± 0.62 24 0.27 - 4.20
BMI, Body mass index; BUN, Blood urea nitrogen; ALT, Alanine
aminotransferase; AST, Aspartate aminotransferase; TSH, Thyroid
stimulating hormone.
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The epidemiological establishment of diabetes as a risk fac-
tor for cardiovascular disease is well demonstrated [1].
Even before the development of frank diabetes, insulin re-
sistance causes disturbed lipid transport in plasma [2]. Pa-
tients with type 2 diabetes mellitus (T2DM) are frequently
associated with low total high-density lipoprotein choles-
terol (HDL-C) levels, high levels of small dense LDL and
elevated triglyceride (TG) levels [3]. This triad is referred
to as the atherogenic lipid profile, which is observed due to
insulin resistance [4].
Targeting and treating dyslipidemia improves long-term
prognosis in type 2 diabetes [5]. However, despite interven-
tion, these patients remain at increased risk for vascular
complications [6], suggesting that other factors may con-
tribute. A part of the increased cardiovascular disease risk
in T2DM may be attributed to qualitative changes in lipo-
protein subfractions. Although concentrations of Low-
density lipoprotein cholesterol (LDL-C) may not be ele-
vated in type 2 diabetes, the dyslipidemia is characterized
by an increased proportion of small dense LDL [7] which
easily filter into the subendothelial space, are retained by
proteoglycans there and are easily oxidized [8]. Indeed, in-
creased small dense LDL particles have been shown to be
associated with increased risk of myocardial infarction [9].
Cardiovascular disease risk in T2DM may also be in-
creased by qualitative changes in HDL subfractions with
an increased proportion of HDL occurring as smaller,
dense HDL [10]. Epidemiological studies showed a pre-
dominance of small HDL particles among patients with
coronary heart disease as compared with control subjects
[11]. HDL also exhibits various anti-atherogenic, anti-
oxidant, anti-inflammatory and anti-thrombotic properties
[12]. An essential role in these beneficial functions may be
played by enzymes and proteins associated with this lipo-
protein such as cholesteryl ester transfer protein (CETP),
lecithin-cholesterol acyltransferase (LCAT), paraoxonase
(PON1) and apoA-I [12].
Although it has been shown that, 2 weeks continuous
subcutaneous insulin infusion (CSII) achieved good gly-
cemic control and resulted in an improvement in lipid pa-
rameters in newly diagnosed type 2 diabetic patients with
fasting glucose levels >200 mg/dl [13], the effect of insulin
analog initiation therapy on LDL/HDL subfraction profile
and HDL associated enzymes in type 2 diabetic patients
has not been established. The aim of this study was to de-
termine the short term effect of insulin analog initiation
therapy on LDL/HDL sub-fractions and HDL associated
enzymes in type 2 diabetic patients.
Materials and methods
Patients
The study group included 24 patients who were admitted
to Antalya Research and Education Hospital, EndocrinologyClinic with a diagnosis of T2DM. Patient characteristics
and laboratory values are shown in Table 1. The body mass
index (BMI) of all patients enrolled in the study was <30
kg/m2 and all were non-smokers. None of the patients re-
ceived antilipidemic agents in the last 3 months before the
study. Subjects with apparent history of stroke, coronary
heart disease, peripheral artery disease, severe kidney dys-
function, liver disease, thyroid dysfunction, infectious dis-
ease, and malignancy were excluded. All subjects enrolled
were maintained on a standardized diet before the initiation
of the study. HbA1c levels in all patients were above 10%
despite ongoing therapy with sulphonylurea and metformin
for at least 3 months. Former treatment regimen was con-
tinued for the first day followed by substitution of
sulphonylurea therapy with different insulin analogs. Pa-
tients received either 0.4 U/kg/day lispro mix (50% insulin
lispro protamine and 50% insulin lispro) subcutaneously
(SC) in three equal doses plus 2000 mg/day oral metformin;
0.4 U/kg/day insulin aspart (30% insulin aspart and 70%
protamine insulin aspart) SC in two equal doses plus 2000
mg/day oral metformin; or 0.4 U/kg/day insulin glargine
SC in one dose plus 2000 mg/day oral metformin. The
given insulin treatments were in accordance with American
Association of Clinical Endocrinologists (AACE) Diabetes
Mellitus guidelines [14]. All patients gave written informed
consent prior to entry. This study was approved by the In-
stitutional Review Board of Antalya Research and Educa-
tion Hospital and was performed in accordance with the
Declaration of Helsinki.
Continuous glucose monitoring
All patients were equipped with continuous glucose
monitoring system (CGMS; Medtronic Mini-Med, USA)
and were monitored for 72 consecutive hours after ad-
mission. A CGMS sensor was inserted into the subcuta-
neous abdominal fat tissue and calibrated according to
the standard Medtronic MiniMed operating guidelines.
During CGMS monitoring, blood glucose levels were
checked via a glucometer (Accu-Check Go, Roche Co.) 4
Table 2 Mean blood glucose and lipid profile before and




treatment n p value
(mean ± SD) (mean ± SD)
Glucose (mg/dl) 215.46 ± 53.04 177.29 ± 54.48* 24 <0.001
Total Cholesterol
(mg/dl)
212.50 ± 40.48 203.29 ± 38.86* 24 0.033
TG (mg/dl) 257.29 ± 171.87 210.25 ± 130.39* 24 0.001
VLDL-C (mg/dl) 51.45 ± 34.37 42.05 ± 26.08* 24 0.001
LDL-C (mg/dl) 133.40 ± 35.17 125.62 ± 40.06 23 0.379
HDL-C (mg/dl) 33.20 ± 9.28 35.63 ± 10.18* 24 0.003
TG, Triglyceride; VLDL-C, Very low-density lipoprotein cholesterol; LDL-C,
Low-density lipoprotein cholesterol; HDL-C, High-density
lipoprotein cholesterol.
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After monitoring for 72 hours, the recorded data were
downloaded into a personal computer for analysis of the
glucose profile. After downloading the recorded data,
mean blood glucose levels were analyzed from the data.
Laboratory measurements
Blood were obtained from all patients at 24 and 72 hours.
HbA1c levels were determined by Abbott ARCHITECT
c16000 System (Abbott Diaognostic, Abbott Park Illinois,
USA) via immunoturbidimetric method. Total cholesterol
(TC), HDL-C and TG were measured on Roche Cobas
8000 Modular Analyser (Basel, Switzerland) via enzymatic
colorimetric methods. LDL-C and very low-density lipo-
protein cholesterol (VLDL-C) levels were calculated via the
Friedewald formula [15]. Blood urea nitrogen (BUN),
serum creatinine, alanine aminotransferase (ALT), and as-
partate aminotransferase (AST) were measued on Roche
Cobas 8000 Modular Analyser via colorimetric methods.
Serum thyroid stimulating hormone (TSH) and urine
microalbumin was measured on Roche Cobas 8000 Modu-
lar Analyser via electrochemiluminescence immunoassay
and turbidimetric methods, respectively.
LDL subfraction analysis
LDL subfraction analysis was performed electrophoretically
by use of high-resolution 3% poylacrylamide gel tubes and
the Lipoprint LDL System [Quantimetrix, Redondo Beach,
California (CA), USA] according to the manufacturer’s in-
structions [16]. Briefly, 25 μL of sample was mixed with
200 μL of liquid loading gel. The loading gel contained
Sudan Black B dye to stain the lipoproteins. The resulting
mixture was added to the top of precast 3% polyacrylamide
gel tubes. After photopolymerization at room temperature
for 35 min, samples were electrophoresed for 1 hour 5 mi-
nutes (3 mA/gel tube). Densitometry was performed by
Microtek ArtixScan M1 system and data was analyzed by
Quantimetrix software (Lipoware-Research version) aspreviously described [16,17]. In this method, VLDL remains
in the origin [retention factor (Rf) = 0.0], whereas HDL mi-
grates at the front (Rf = 1.0). In between, several bands can
be detected: Middle (MID) bands C, B, and A, which cor-
respond mainly to intermediate-density lipoprotein (IDL),
as well as the LDL bands. LDL1 and LDL2 bands corres-
pond to large, buoyant LDL particles, whereas bands LDL3
and above correspond to sdLDL particles. VLDL and the
proportion (%) of the cholesterol mass (mg/dl) of LDL
subfractions over the total LDL-C mass were calculated by
Quantimetrix software.
HDL subfraction analysis
Analysis of the apoA-I–containing lipoprotein subfractions
was performed using Lipoprint HDL System (Quantimetrix,
Redondo Beach, CA, USA) as previously described [18].
Briefly, 25 μl of sample was mixed with 300 μl of Lipoprint
Loading Gel and placed upon the upper part of the
high-resolution 3% polyacrylamide gel. After 35 min of
photopolymerization at room temperature, electrophoresis
was performed for 55 min with 3mA for each gel tube.
After electrophoresis, VLDL and LDL remained at the origin
[Rf = 0.0], whereas albumin migrated at the front (Rf = 1.0).
In between, up to 10 bands of HDL can be detected. HDL1
through HDL3 are defined as large HDL; HDL4 through
HDL7 are defined as intermediate HDL and HDL8 through
HDL10 comprise the small HDL portion. Cholesterol con-
centration of each HDL subfraction was determined by
multiplying the relative area under the curve of each
subfraction by the HDL-C concentration of the sample.
CETP protein and activity measurement
Serum CETP concentrations were analyzed by a commer-
cial enzyme-linked immunosorbent assay (ELISA) test kit
[47-CETHU-E01; ALPCO, Salem, New Hampshire (NH),
USA] according to the manufacturer’s instructions. Test
wells were coated with anti-CETP Monoclonal antibody
(Ab). CETP in the sample was captured by the antibody in
the 1st incubation. After the 1st incubation and washing to
remove all of the unbound material, horseradish peroxidase
(HRP)-labeled anti-CETP Monoclonal Ab was added. After
the 2nd incubation and subsequent washing, substrate solu-
tion was added. Next, stop reagent was added and the in-
tensity of color that develops was measured at 492 nm by a
microplate reader. A standard curve of absorbance values
of known CETP standards was plotted as a function of the
logarithm of CETP standard concentrations (μg/ml) using
the GraphPad Prism Software program for windows version
5,03. (GraphPad Software Inc). CETP concentrations in the
samples were calculated from their corresponding absorb-
ance values via the standard curve.
Serum CETP activity was measured using an assay kit fol-
lowing the manufacturer’s instruction (BioVision, Mountain
View, CA, USA). Briefly, 3 μl of plasma sample (as the
AB
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Figure 1 Electrophoretic separation of lipoproteins on the Quantimetrix Lipoprint Low-Density Lipoprotein System. (A) Image of
electrophoretic migration of 6 gel tubes. BT, before treatment; AT, after treatment. (B) Demonstrative densitometric scan of a sample before
treatment with insulin analogs (C) Demonstrative densitometric scan of a sample after treatment with insulin analogs.
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Table 3 Low-density lipoprotein subfraction analysis
results before and after insulin analog initiation therapy
Variable Before treatment After treatment n p
value(mean ± SD) (mean ± SD)
IDL-C (mg/dl) 29.63 ± 6.08 28.83 ± 5.48 24 0.481
IDL-B (mg/dl) 14.57 ± 3.68 13.99 ± 3.97 24 0.234
IDL-A (mg/dl) 14.48 ± 3.99 14.94 ± 4.54 24 0.380
LDL-1 (mg/dl) 35.57 ± 10.62 37.96 ± 11.37* 24 0.025
LDL-2 (mg/dl) 31.56 ± 10.23 27.68 ± 8.74* 24 0.011
LDL-3 (mg/dl) 7.50 ± 6.20 5.33 ± 4.68* 24 0.003
LDL-4 (mg/dl) 3.04 ± 2.45 1.70 ± 1.76* 9 0.018
IDL, Intermediate-density lipoprotein; LDL, Low-density lipoprotein.
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containing a fluorescent self-quenched neutral lipid as the
donor molecule and an acceptor molecule. A CETP-
mediated transfer of the fluorescent neutral lipid to the ac-
ceptor molecule resulted in an increase in fluorescence,
which was read in a fluorescence plate reader at excitation
465 nm and emission 535 nm. A standard curve was pre-
pared by using known concentrations (0–100 pmol) of
fluorescent neutral lipid standards. CETP activity in the
samples was calculated from the corresponding fluores-
cence values via the standard curve and was expressed as
pmol/μl sample/hr.
LCAT protein and activity measurement
Serum LCAT concentrations were analyzed by a commer-
cial ELISA test kit (47-LCAHU-E01; ALPCO, Salem, NH,
USA) according to the manufacturer’s instructions. Test
wells were coated with anti-LCAT monoclonal antibody,
which binds with LCAT in the sample. After the first incu-
bation and washes to remove all of the unbound material,
HRP-labeled anti-LCAT was added. After the second in-
cubation and subsequent washes, the antibody / LCAT /
enzyme complex was incubated with a substrate solution
and terminated with a stop reagent. The intensity of color
that develops was measured at 492 nm by a microplate
reader. A standard curve of absorbance values of known
LCAT standards was plotted as a function of the logarithm
of LCAT standard concentrations (μg/ml) using the
GraphPad Prism Software program for windows version
5,03. (GraphPad Software Inc). LCAT concentrations in
the samples were calculated from their corresponding ab-
sorbance values via the standard curve.
Plasma LCAT activity was assayed using the Calbiochem
Fluorometric LCATassay kit (EMD Bioscience, San Diego,
CA, USA) according to the manufacturer’s instructions.
This assay is based on the hydrolysis of an artificial LCAT
substrate that fluoresces at 470 nm, resulting in a product
that fluoresces at 390 nm. Aliquotes of 3 μl of plasma were
mixed with 1 μl of fluorescent LCAT substrate and 200 μl
of LCAT assay Buffer, followed by incubation for 5 hr at37°C. The reaction was stopped by adding 300 μl of READ
reagent (provided in the kit) to 100 μl of the reaction mix-
ture, followed by fuorometry at 390 and 470 nm. LCAT
activity is defined as the change in the ratio of 390/470
nm fluorescence emission intensities.
Apolipoprotein A1 and B measurements
Serum apoAI levels were determined with the Human
ApoAI ELISA kit [no. 3710–1HP-2; Mabtech, Cincinnati,
Ohio (OH), USA] according to the manufacturer’s instruc-
tions. Samples (diluted 500 000x) were added to ELISA
strip plates precoated with apoA1 monoclonal antibody
(mAb). Captured apoA1 in the samples were detected by
adding a biotinylated mAb followed by streptavidin-HRP.
Addition of 3,3’,5,5’ tetramethylbenzidine (TMB) resulted
in a colored enzyme substrate solution and the reaction
was terminated with a stop reagent. The intensity of color
that developed was measured at 450 nm by a microplate
reader. A standard curve of absorbance values of known
apoA1 standards was plotted as a function of the loga-
rithm of apoA1 standard concentrations (ng/ml) using the
GraphPad Prism Software program for windows version
5,03. (GraphPad Software Inc). ApoA1 concentrations in
the samples were calculated from their corresponding ab-
sorbance values via the standard curve.
Serum apoB levels were determined with the Human
ApoB ELISA kit (no. 3715–1HP-2 Mabtech, Cincinnati,
OH, USA), according to the manufacturer’s instruc-
tions. This kit is specific for detection of apoB100. Sam-
ples (diluted 16000 x) were added to ELISA strip plates
precoated with apoB100 monoclonal antibody (mAb).
Captured apoB100 in the samples were detected by
adding a biotinylated mAb followed by streptavidin-
HRP. Addition of 3,3’,5,5’ tetramethylbenzidine (TMB)
resulted in a colored enzyme substrate solution and the
reaction was terminated with a stop reagent. The inten-
sity of color that develops was measured at 450 nm by a
microplate reader. A standard curve of absorbance values
of known apoB100 standards was plotted as a function of
the logarithm of apoB100 standard concentrations (ng/ml)
using the GraphPad Prism Software program for windows
version 5,03. (GraphPad Software Inc). ApoB100 concen-
trations in the samples were calculated from their corre-
sponding absorbance values via the standard curve.
PON1 activity measurement
Serum PON1 activity was determined by a commercial
assay kit [ZMC catalogue # 0801199; Zeptometrix Cor-
poration, Buffalo, New York (NY), USA] according to
the manufacturer’s instructions. This assay is based on
the principle that PON1 catalyzes the cleavage of phenyl
acetate, resulting in phenol. The rate of formation of
phenol was measured by monitoring the increase in ab-
sorbance at 270 nm, at 25°C. One unit of arylesterase
BC






Figure 2 Electrophoretic separation of lipoproteins on the Quantimetrix Lipoprint High-Density Lipoprotein System. (A) Image of
electrophoretic migration of 6 gel tubes. BT, before treatment; AT, after treatment. (B) Demonstrative densitometric scan of a sample before
treatment with insulin analogs (C) Demonstrative densitometric scan of a sample after treatment with insulin analogs.
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Table 4 High-density lipoprotein subfraction analysis
results before and after insulin analog initiation therapy
Parameter Before treatment After treatment n p
value(mean ± SD) (mean ± SD)
HDL-1 (mg/dl) 2.88 ± 1.60 3.88 ± 1.93* 24 0.005
HDL-2 (mg/dl) 4.43 ± 2.13 5.01 ± 2.32* 24 0.027
HDL-3 (mg/dl) 2.46 ± 1.10 3.01 ± 1.16* 24 0.001
HDL-4 (mg/dl) 3.79 ± 1.59 4.67 ± 1.39* 24 0.001
HDL-5 (mg/dl) 4.69 ± 1.44 5.15 ± 1.24* 24 0.015
HDL-6 (mg/dl) 7.72 ±2.19 7.82 ± 2.41 24 0.761
HDL-7 (mg/dl) 2.28 ± 0.94 1.99 ±0.82 24 0.204
HDL-8 (mg/dl) 1.90 ± 0.76 1.61 ± 0.60 24 0.058
HDL-9 (mg/dl) 1.56 ± 0.50 1.36 ± 0.60 24 0.204
HDL-10 (mg/dl) 1.42 ± 0.89 0.93 ± 0.58* 24 0.010
HDL-Large (mg/dl) 9.57 ± 4.20 12.03 ± 5.25* 24 0.001
HDL-Inter. (mg/dl) 18.51 ± 4.99 19.86 ± 5.00* 24 0.018




























































































Figure 3 Box plot graph data of (A) plasma cholesteryl ester
transfer protein (CETP) levels (B) CETP activity (C) lecithin-
cholesterol acyltransferase (LCAT) protein levels (D) LCAT activity.
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The activity is expressed in kU/L, based on the extinc-
tion coefficient of phenol of 1310 M-1cm-1 at 270 nm at
pH 8.0 and at 25°C. Blank samples containing water
were used to correct for nonenzymatic hydrolysis.
Statistical analysis
Data were analyzed using Sigma Stat (version 2.03) stat-
istical software for Windows, and a P value < 0.05 was
considered statistically significant.
Results
We performed a two way analysis of variance (ANOVA)
to determine whether the three different insulin regimens
showed any difference among the reported variables. The
subgroup analysis did not uncover any differences between
the insulin regimens. Therefore we pooled the groups, and
reported the data as before and after insulin treatment.
Blood glucose and lipid profile
Mean blood glucose, TC, TG and VLDL-C levels were
significantly decreased while HDL-C levels were signifi-
cantly increased after treatment with insulin analogs plus
metformin compared to before treatment levels (Table 2).
Although not significant, a decrease was also observed
in LDL-C levels after treatment with insulin analogs plus
metformin (Table 2). Statistical analysis was done by
paired t-test.
Changes in LDL subfraction pattern
Figure 1A shows 6 gel tubes [3 before treatment (BT) and
3 after treatment (AT) with insulin analogs] following com-




















































Figure 4 Box plot graph data of (A) Apolipoprotein B 100
protein levels (B) Apolipoprotein A-1 protein levels (C)
paraoxonase (PON1) activity.
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achieved via particle size based on the sieving action of the
gel. Chylomicrons remained in the loading gel, VLDL was
the slowest migrating band while HDL migrated to a fur-
ther distance. The LDL particles were separated in themiddle part of the gel. Bands corresponding to large, buoy-
ant LDL particles showed clear increase in intensity after
treatment with insulin analogs. Figure 1B and 1C are de-
monstrative densitometric scans of before and after treat-
ment with insulin analogs, respectively. A significant
increase in LDL-1 fraction and a significant decrease in
LDL-2, LDL-3 and LDL-4 fraction were seen after treat-
ment with insulin analogs (Figure 1B, 1C and Table 3).
Statistical analysis was done by paired t-test.
Changes in HDL subfraction pattern
Figure 2A shows 6 gel tubes [3 before treatment (BT) and
3 after treatment (AT) with insulin analogs] following
completion of electrophoresis. Electrophoretic migration
was from the top of the tube to the bottom. Separation
was achieved via particle size based on the sieving action
of the gel. LDL/VLDL was the slowest migrating band
while albumin migrated to a further distance. The HDL
particles were separated in the middle part of the gel.
Bands corresponding to large- and intermediate-HDL par-
ticles showed clear increase in intensity after treatment
with insulin analogs. Figure 2B and 2C are demonstrative
densitometric scans of before treatment and after treat-
ment with insulin analogs, respectively. A significant in-
crease in HDL-large (HDL-1,-2 and-3); HDL-intermediate
(HDL-4 and −5) and a significant decrease in HDL-small
(HDL-10) fraction were seen after treatment with insulin
analogs (Figure 2B, 2C and Table 4). Statistical analysis
was done by paired t-test.
CETP and LCAT level and activity
Box plot graph data of CETP and LCAT protein content
and activity are shown in Figure 3. The boundary of the
box closest to zero indicates the 25th percentile, the line
within the box marks the median, and the boundary of
the box farthest from zero indicates the 75th percentile.
Whiskers above and below the box indicate the 90th and
10th percentiles.
CETP protein (mean ± SD) measured after treatment
with insulin analogs (2.32 ± 0.51 μg/ml) was signifi-
cantly increased (p < 0.001) compared to before treat-
ment level (2.10 ± 0.39 μg/ml) (Figure 3A). Statistical
analysis was done by Wilcoxon Signed Rank Test. Simi-
larly, CETP activity (mean ± SD) measured after treat-
ment with insulin analogs (33.53 ± 6.90 pmol/μl/hr)
was significantly increased (p = 0.025) compared to be-
fore treatment (30.05 ± 7.15 pmol/μl/hr) (Figure 3B).
Statistical analysis was done by paired t-test.
No significant difference was observed in LCAT pro-
tein level (mean ± SD) before and after treatment with
insulin analogs with measured level of 11.93 ± 2.93 and
12.94 ± 3.05 μg/ml, respectively (Figure 3C). Similarly,
no significant difference was observed in LCAT activity
(mean ± SD) before and after treatment with insulin
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emission intensities of 1.36 ± 0.14 and 1.30 ± 0.22, re-
spectively (Figure 3D).
Apolipoprotein A1 and B levels
Apolipoprotein B level (mean ± SD) measured after treat-
ment with insulin analogs (1.25 ± 0.49 g/L) was signifi-
cantly decreased (p = 0.006) compared to before treatment
(1.63 ± 0.37 g/L) (Figure 4A). Statistical analysis was done
by paired t-test.
No significant difference was observed in apoA protein
level (mean ± SD) before and after treatment with insulin
analogs with measured levels of 1.53 ± 0.35 and 1.43 ±
0.49 g/L, respectively (Figure 4B).
PON1 activity
No significant difference was observed in PON-1
arylesterase activity (mean ± SD) before and after treat-
ment with insulin analogs with measured levels of
91.43 ± 19.33 kU/L and 94.77 ± 18.05 kU/L, respect-
ively (Figure 4C).
Discussion
Achieving and maintaining glycemic control in type 2 dia-
betic patients is challenging due to the gradual loss of en-
dogenous insulin secretion and the presence of insulin
resistance. The majority of patients are unable to maintain
HbA1c targets on a treatment regimen of oral antidiabetic
drugs [19]. Thus, addition of insulin therapy is an import-
ant step towards achieving long-term glycemic control
and reducing the risk of micro- and macrovascular com-
plications [20]. We therefore substituted sulphonylurea
therapy with different insulin analogs in patients enrolled
in this study.
Modifications of the insulin molecule have resulted in
both long-acting insulin analogs such as glargine [21] and
rapid-acting insulin analogs such as aspart [22] and lispro
[23]. These insulin analogs are reported to have an im-
proved pharmacokinetic/pharmacodynamic profile [24].
Patients enrolled in our study received either lispro mix
(50% insulin lispro protamine and 50% insulin lispro) in
three equal doses; insulin aspart (30% insulin aspart and
70% protamine insulin aspart) in two equal doses or insulin
glargine in one dose. It has been reported that rapid-acting
insulin analogs have a faster onset and shorter duration of
action than regular human insulin, provide better control
of postprandial plasma glucose concentrations [25]. Simi-
larly, Glargine has been shown to provide up to 24-hour
glucose control than Neutral protamine Hagedorn (NPH)
insulin in patients with type 2 diabetes [26]. A recent
guideline from the AACE and the American College of
Endocrinology notes that insulin analogs yield better repro-
ducibility and consistency between and within patients
[27]. In agreement with reported studies, we have observedthat treatment with insulin analog plus metformin resulted
in a significant reduction in mean blood glucose levels, as
determined by CGMS data.
This investigation demonstrated for the first time that
very short-duration insulin therapy (3 days) can significantly
alter lipoprotein concentrations in very poorly-controlled
Type 2 Diabetic patients who are receiving no lipid therapy.
These changes are similar to previous insulin studies but
those studies investigated treatment periods from weeks to
months and their subjects were not as poorly controlled
[13,28]. A more detailed lipoprotein compositional analysis
was performed within this study than previous trials. The
factors measured within this study would be expected to
contribute to changes in lipoprotein composition.
We have observed that TC, TG and VLDL levels were sig-
nificantly decreased while HDL-C levels were significantly
increased after treatment with insulin analogs plus metfor-
min compared to before treatment levels. These findings are
in agreement with a previous study that has shown that, 2
weeks CSII achieved good glycemic control and resulted in
an improvement in lipid parameters in newly diagnosed type
2 diabetic patients with fasting glucose levels >200 mg/dl
[13]. Decreased TC, LDL-C and TG levels and increased
HDL-C was observed following short term CSII in the
reported study [13]. Similar results were found in another
study evaluating the long term (30 weeks) effects of CSII on
dyslipidemia in type 2 diabetics without previous history of
major cardiovascular disease [28].
We have observed an approximately 17% significant
decrease in mean blood glucose levels 48 h after the ini-
tiation of insulin analog therapy. According to AACE,
insulin therapy should target HbA1c levels of 6.5% or
less for most adults [29]. The estimated average glucose
level (mg/dl) which corresponds to 7% HbA1c level is
reported to be 154 mg/dl (123–185) [30]. Although the
achieved reduction in mean blood glucose levels in our
study (177.29 ± 54.48 mg/dl) was above the reported tar-
get [29,30], we still observed an improvement in lipid
parameters as shown in Table 2. Thus, insulin analog
initiation therapy has shown beneficial effects on lipo-
protein profile in a very short period of time.
We have seen a significant increase in LDL-1 fraction
and a significant decrease in LDL-2, LDL-3 and LDL-4
fractions after treatment with insulin analogs. Our findings
are in agreement with a previous study that has shown that
insulin therapy independently of variations in blood glu-
cose control induces an improvement in LDL subfraction
distribution with a shift toward a decrease in small dense
LDL in type 2 diabetic patients [31].
We have observed that insulin analog initiation ther-
apy caused a significant increase in HDL-large, HDL-
intermediate and a significant reduction in HDL-small
subfractions. Our data is in agreement with a previous
study which has reported that intensive insulin therapy
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cies in type 2 diabetic patients [32]. The observed in-
crease in both LDL-1 and large HDL fractions following
insulin therapy may be attributed to the reduction in
circulating triglycerides. CETP mediates the transfer of
TG from VLDL to HDL and/or LDL in exchange for
cholesteryl ester (CE) [33]. It is important to note that
CETP does not drive triglycerides or cholesterol esters
in one direction or another but is simply a shuttle pro-
tein for whatever lipids are available [33]. It is likely that
the reduction in circulating triglycerides reduced the ex-
change of triglycerides in VLDL for cholesterol esters in
HDL and LDL, thus, returning them to their normal
composition of more large particles and fewer small
particle. Our finding of increased CETP activity is in
agreement with previous studies which have also shown
that insulin treatment increased CETP activity and im-
proved postprandial lipemia [34,35].
We have observed that insulin treatment significantly
decreased ApoB levels. ApoB can be degraded in response
to decreased VLDL secretion following insulin therapy
[36]. When insulin binds to its receptor, the receptor is ac-
tivated by phosphorylation on tyrosine residues, which
phosphorylates insulin receptor substrates 1 (IRS1) and
IRS2. The phosphotyrosine residues act as docking sites
for the p85 regulatory subunit of phosphatidylinositide 3’
kinase (PI3K) [36]. Insulin suppresses hepatic VLDL pro-
duction through activation of PI3K [37]. Activated PI3K
can be localized to membranes which allows the forma-
tion of phosphatidylinositide (3,4,5) triphosphate (PIP3)
from phosphatidylinositide (4,5) biphosphate (PIP2). PIP3
is a highly negatively charged phospholipid which may
interfere with TG addition into VLDL precursors, thereby
reducing the formation of VLDL. VLDL precursors unable
to accept lipid droplets are targeted for degradation in ly-
sosomes [38]. ApoB can be degraded in response to de-
creased VLDL secretion. VLDL overproduction and the
loss of insulin suppression of apoB secretion occur in pa-
tients with type 2 diabetes [38].
We observed no significant difference in PON-1
arylesterase activity after treatment with insulin analogs.
Purified human PON-1 is one of the important compo-
nents of HDL [39]. PON-1 hydrolyzes several substrates
including organophosphates, carboxylic acid esters, lac-
tones and oxidized phospholipids [40]. While over the
years enzymatic activity has been named with regard to
the substrates required, the same enzyme has been
shown to catalyze nearly all arylesterase and para-
oxonase activities [41]. The PON-1 activities that have
been mostly studied are those towards paraoxon
(paraoxonase activity) and phenyl acetate (arylesterase
activity) [42]. The PON-1 assay performed in our study
was based on the cleavage of phenyl acetate resulting in
the formation of phenol.Conclusion
In summary, we have observed that insulin analog initiation
therapy up-regulates CETP, increases LDL-1 and HDL-large,
decreases LDL-3, LDL-4 and small HDL subfractions in a
short period of time. The observed changes in lipoprotein
profile and CETP occur even though the reduction in mean
blood glucose levels are still above the desired target values.
Further studies are needed to evaluate the molecular mecha-
nisms by which insulin analogs alter lipoprotein distribution
and associated enzymes in reverse cholesterol transport.
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